Zilovertamab vedotin

Phase 3Antibody–drug conjugate

Zilovertamab vedotin is one of 129 biologic programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Large B-Cell LymphomaRecruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

DLBCLRecruiting

Lymphoma, Large B-Cell, DiffuseRecruiting

Urothelial CarcinomaActive, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

DLBCLPreclinical

Recruiting

Lymphoma, Large B-Cell, DiffusePhase 2

Recruiting

Urothelial CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

367 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 3

58 2

Rituxan

Venclexta

50 4

Calquence

AstraZeneca

Phase 3

23 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

42 6

Nipent

Pfizer

Phase 3

13 7

Brukinsa

BBeOne Medicines

Phase 3

15 8

Adcetris

Pfizer

Phase 3

1 9

Medrol

Pfizer

Phase 3

1 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

DLBCL

NCT05139017

Q2 2028

Phase 1/2Active, not recruiting

Urothelial Carcinoma

NCT05562830

Q1 2029

Phase 1/2Recruiting

Hematologic Malignancies

NCT06395103

Q2 2029

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05406401

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT05458297

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma3 trials

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05406401·60 enrolled

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05144841·140 enrolled

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Hematologic Malignancies2 trials

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03833180·91 enrolled

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06395103·90 enrolled

Urothelial Carcinoma1 trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT05562830·48 enrolled

Solid Tumors1 trial

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT04504916·102 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

2 more indications

Chronic Lymphocytic Leukemia1 trial

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05458297·189 enrolled

DLBCL1 trial

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05139017·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Zilovertamab vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zilovertamab vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zilovertamab vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Zilovertamab vedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma3 trials

Hematologic Malignancies2 trials

Urothelial Carcinoma1 trial

Solid Tumors1 trial

Lymphoma, Large B-Cell, Diffuse1 trial

Chronic Lymphocytic Leukemia1 trial

DLBCL1 trial

References

Drug Info

Quick Facts

Related News